Immune Booster Cells Show Promise After Checkpoint Blockers in Liver Cancer
A Taiwanese preliminary study found that following a short course of immune checkpoint inhibitors with infusions of tumor-primed dendritic cells ...
A Taiwanese preliminary study found that following a short course of immune checkpoint inhibitors with infusions of tumor-primed dendritic cells ...
Johns Hopkins researchers measured the metabolism of immune cells inside human head and neck tumors and found that exhausted T ...
A phase 2 trial found that brentuximab vedotin and nivolumab added to limited chemotherapy produced a 92 percent complete response ...
A Japanese case report describes more than three years of progression-free survival in pulmonary tumour thrombotic microangiopathy after prompt nivolumab ...
A retrospective review of 35 published cases shows that nivolumab can trigger cytokine release syndrome weeks to months into treatment, ...
A revised meta-analysis of six phase III trials shows first-line PD-1 inhibitor plus chemotherapy reduces the risk of death by ...
A high tumor mutational burden detected by liquid biopsy guided nivolumab treatment that produced a durable complete remission in a ...
A large UK pan-cancer study finds no consistent link between the season of checkpoint inhibitor initiation and overall survival, despite ...
Highlighted studies at the 2026 ASTRO Annual Meeting in Boston span hypofractionated radiotherapy trials, proton versus photon therapy for liver ...
A sweeping 2024–2025 evidence review shows immune checkpoint inhibitors, frailty-adapted surgery, and artificial intelligence converging to transform esophageal cancer treatment ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine